



STATEMENT RE: LA ACT 246
Sept. 27, 2024

Contact: PR@ochsner.org

Ochsner Health continues to provide care for patients in accordance with the law, using misoprostol when it is clinically indicated, following the protocols in place for all controlled substances. We respect the guidance in Louisiana Act 246 and have updated our processes to be compliant with the law and also ensuring that misoprostol will be readily and immediately available in Labor & Delivery units across the system, including in emergency situations.

As with all controlled substances, misoprostol can be prescribed with clear documentation of clinical condition with accompanying diagnosis codes both in the patient's medical record and the prescription/order by any provider with a DEA license. It is standard practice to securely store certain medical supplies in patient care areas. All controlled substances and the majority of non-controlled substances are stored in locked drawers.

We appreciate the close collaboration with the Louisiana Department of Health, the Attorney General and other government partners in developing these protocols. With respect to New Orleans City Council Motion M-24-499, Ochsner has not previously made a statement related to our position on the proposed study, but to avoid any ambiguity, we do not believe a study is necessary as it relates to protocols at Ochsner. We are confident in the new procedures being implemented, and as always, we remain committed to serving our patients and providing high-quality and compassionate healthcare.

- Dr. Robert Hart, Chief Physician Executive, Ochsner Health and President, Ochsner Clinic